Takeda

News

Takeda's Ninlaro fails phase 3 amyloidosis trial

Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not meet the first of two primary endpoints.

News

Takeda to sell dry eye drug to Novartis for up to $5.3bn

Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts fol

News

NICE backs interim funding for J&J/Takeda myeloma regimen

A three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be made available to patients in England, but only via the Cance

News

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.

News

Takeda mulling sale of emerging market drugs - report

Takeda could be considering selling some emerging-market drugs in a bid to cut debts following its merger with Shire that completed earlier this month, according to a press report.

News

Takeda's Shire takeover could herald new era of pharma M&A

Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma.

Takeda's Ninlaro fails phase 3 amyloidosis trial

Takeda to sell dry eye drug to Novartis for up to $5.3bn

NICE backs interim funding for J&J/Takeda myeloma regimen

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda mulling sale of emerging market drugs - report

Takeda's Shire takeover could herald new era of pharma M&A

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Takeda

Editor's Picks